Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells

Hachmo et al. (2020, Aging) made international headlines because it was the first published human trial to show that a non-pharmacological intervention could lengthen telomeres and clear out senescent cells — two of the most-studied hallmark biomarkers of biological aging. What the trial measured. Two primary cellular outcomes: telomere length across multiple immune cell subtypes (T helper cells, T cytotoxic cells, natural killer cells, and B cells), and senescent cell populations within the T helper and T cytotoxic compartments. These are the biomarkers most-cited in the López-Otín 'hallmarks of aging' framework, so the paper was deliberately designed to address whether HBOT could move them. Who was studied. Thirty-five healthy, independently-living adults — the cohort was deliberately not selected for any disease state, which is what makes the result striking. The participants were not seeking HBOT for a clinical condition; they were healthy older adults receiving the intervention as a longevity protocol. Protocol parameters. Sixty daily HBOT exposures over approximately three months. Per the published protocol, sessions used 100% oxygen at 2.0 ATA with intermittent air breaks (the design that engages the 'hyperoxic-hypoxic paradox' driving the regenerative response). Blood draws were taken at baseline, during the protocol, at the end of the protocol, and 1–2 weeks after the final session. Results. The headline finding was that telomere length increased significantly across all four measured immune cell subtypes — by over 20% on average. B cells showed the largest gain at 37.63% ± 52.73 (p=0.007). Senescent T-helper cells decreased by 37.30% ± 33.04 (p<0.0001) — meaning a substantial fraction of zombie immune cells were cleared. These are large effect sizes for a non-pharmacological intervention. Limitations. Sample size was modest (n=35) and the cohort skewed older, healthy, and Israeli; generalizability to other populations is not yet confirmed. The protocol was aggressive (60 sessions at 2.0 ATA) and would be hard to replicate at home. The trial measured cellular biomarkers, not lifespan or healthspan endpoints — those would require multi-decade follow-up. And the mechanisms by which oxygen fluctuation drives telomere lengthening are inferred from in vitro literature, not directly proven in this paper. What it means in practice. The Hachmo 2020 protocol — 60 sessions, 2.0 ATA, 100% oxygen with air breaks, 90-minute sessions — is the directly-cited reference for HBOT longevity protocols on the Saturate site. For users running 1.5 ATA home protocols, the mechanism (hyperoxic-hypoxic paradox) is preserved at lower pressure but no published trial has confirmed equivalent telomere effects at 1.5 ATA over a longer course. How it relates to other indexed trials. Hachmo 2020 served as the parent cohort for the Hachmo 2021 skin-biopsy substudy (which documented collagen density, elastic fiber, and angiogenic gains). The same Israeli group's Hadanny 2020 cognitive trial in healthy older adults reported attention and processing-speed gains using a parallel protocol. Together these three papers form the most comprehensive single-cohort longevity evidence base in HBOT. First author note: this paper is sometimes cited as 'Hadanny et al.' in popular press because Hadanny is the senior author. The first author is Hachmo. The Saturate citation reflects the bibliographic record. Source: PubMed PMID 33206062.